{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:09:38Z","timestamp":1751083778561,"version":"3.41.0"},"reference-count":126,"publisher":"Scientific Scholar","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arabian Journal of Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.arabjc.2021.103385","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T15:44:31Z","timestamp":1629128671000},"page":"103385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Scoping insight on antiviral drugs against COVID-19"],"prefix":"10.25259","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-8177","authenticated-orcid":false,"given":"Ahmed S.","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulhadi S.","family":"Burzangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragia H.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8488-6579","authenticated-orcid":false,"given":"Hanin S.","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-6890","authenticated-orcid":false,"given":"Hamoud A.","family":"Alsamhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehan","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0005","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2020050589","article-title":"Remdesivir in patients with acute or chronic kidney disease and COVID-19","volume":"31","author":"Adamsick","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0010","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2020.1648","article-title":"Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19","volume":"34","author":"Albariqi","year":"2021","journal-title":"J. Aerosol. Med. Pulm Drug Deliv."},{"key":"10.1016\/j.arabjc.2021.103385_b0025","unstructured":"Aleem, A., Kothadia, J., Remdesivir, in StatPearls. 2021, StatPearls Publishing."},{"key":"10.1016\/j.arabjc.2021.103385_b0030","doi-asserted-by":"crossref","unstructured":"Alexander, P.E., et al., Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis of the Chinese Lancet trial with the NIH trial. medRxiv, 2020: p. 2020.05.23.20110932.","DOI":"10.1101\/2020.05.23.20110932"},{"key":"10.1016\/j.arabjc.2021.103385_b0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.9734\/jpri\/2020\/v32i830468","article-title":"Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile","author":"Ali","year":"2020","journal-title":"J. Pharmaceut. Res. Int."},{"issue":"12","key":"10.1016\/j.arabjc.2021.103385_b0040","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.jsps.2020.09.019","article-title":"Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study","volume":"28","author":"Almazrou","year":"2020","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.arabjc.2021.103385_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.onehlt.2020.100128","article-title":"Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses","volume":"9","author":"Amirian","year":"2020","journal-title":"One Health"},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.arabjc.2021.103385_b0055","first-page":"531","article-title":"Repurposing drugs for COVID-19: Pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine","volume":"13","author":"Babayeva","year":"2020","journal-title":"Pharmacogenomics Pers. Med."},{"issue":"3","key":"10.1016\/j.arabjc.2021.103385_b0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.arcmed.2020.11.006","article-title":"Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies","volume":"52","author":"Baburaj","year":"2021","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.arabjc.2021.103385_b0065","article-title":"Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis","volume":"7","author":"Bansal","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.arabjc.2021.103385_b0070","first-page":"61","article-title":"Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation","volume":"11","author":"Belayneh","year":"2020","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0075","article-title":"Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019\u2014The pilot study","volume":"n\/a(n\/a)","author":"Bistrovic","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.arabjc.2021.103385_b0080","series-title":"Hydroxychloroquine and chloroquine retinopathy","first-page":"35","article-title":"Pharmacology of chloroquine and hydroxychloroquine","author":"Browning","year":"2014"},{"issue":"10","key":"10.1016\/j.arabjc.2021.103385_b0085","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.arabjc.2021.103385_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104898","article-title":"Does lopinavir really inhibit SARS-CoV-2?","volume":"158","author":"Cattaneo","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.arabjc.2021.103385_b0095","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-020-03053-1","article-title":"Prediction of lopinavir\/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts","volume":"77","author":"Cattaneo","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.arabjc.2021.103385_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.138882","article-title":"COVID-19 outbreak: Migration, effects on society, global environment and prevention","volume":"728","author":"Chakraborty","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.arabjc.2021.103385_b0105","doi-asserted-by":"crossref","unstructured":"Chen, P.J., Chao, C.M., Lai, C.C., Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. J. Infect., 2021. 82, 5, p. 199-200.","DOI":"10.1016\/j.jinf.2020.12.005"},{"key":"10.1016\/j.arabjc.2021.103385_b0110","doi-asserted-by":"crossref","unstructured":"Chen, C., et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv, 2020: p. 2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"10.1016\/j.arabjc.2021.103385_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"issue":"5\u20136","key":"10.1016\/j.arabjc.2021.103385_b0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000507423","article-title":"COVID-19 Outbreak: An Overview","volume":"64","author":"Ciotti","year":"2019","journal-title":"Chemotherapy"},{"key":"10.1016\/j.arabjc.2021.103385_b0125","unstructured":"CLINICAL-Trial.gov. Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831. 2021 [cited 2021 15 July]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04480333."},{"key":"10.1016\/j.arabjc.2021.103385_b0130","doi-asserted-by":"crossref","unstructured":"Consortium, W.S.T., Repurposed antiviral drugs for COVID-19\u2014interim WHO SOLIDARITY trial results. New England journal of medicine, 2021. 384, 6, p. 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-020-00952-1","article-title":"Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment","volume":"43","author":"Davies","year":"2020","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ph14070655","article-title":"ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential","volume":"14","author":"Deb","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.arabjc.2021.103385_b0145","first-page":"1","article-title":"Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients","author":"Deb","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.arabjc.2021.103385_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106007","article-title":"Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin","author":"Derendorf","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0155","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arabjc.2021.103385_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100719","article-title":"FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy","volume":"53","author":"Dro\u017cd\u017cal","year":"2020","journal-title":"Drug Resist Updat."},{"key":"10.1016\/j.arabjc.2021.103385_b0165","unstructured":"DRug-Bank(b). Lopinvair 2021 [cited 2021 12 July]; Available from: https:\/\/go.drugbank.com\/drugs\/DB01601."},{"key":"10.1016\/j.arabjc.2021.103385_b0175","unstructured":"Drug-Bank(c). Hyroxychloroquine 2021 [cited 2021 15 July]; Available from: https:\/\/go.drugbank.com\/drugs\/DB01611."},{"issue":"5","key":"10.1016\/j.arabjc.2021.103385_b0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"5","key":"10.1016\/j.arabjc.2021.103385_b0190","first-page":"1","article-title":"In Search for the Truth about Hydroxychloroquine Prophylaxis of Covid-19","volume":"15","author":"Filipova","year":"2021","journal-title":"Health Sci. J."},{"key":"10.1016\/j.arabjc.2021.103385_b0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and its antiviral activity against COVID-19: A systematic review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"Suppl 1","key":"10.1016\/j.arabjc.2021.103385_b0200","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases","volume":"5","author":"Furst","year":"1996","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"FURUTA","year":"2017","journal-title":"Proc. Japan Acad., Ser. B"},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioScience Trends"},{"key":"10.1016\/j.arabjc.2021.103385_b0185","unstructured":"U.S. FDA. (2020). Emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients [Fact Sheet]. Retrieved from https:\/\/www.fda.gov\/media\/136534\/download."},{"key":"10.1016\/j.arabjc.2021.103385_b0215","doi-asserted-by":"crossref","unstructured":"Gautret, P., et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 2020. 56, 1, p. 105949.","DOI":"10.1016\/j.ijantimicag.2020.106063"},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0220","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0006-2952(90)90302-2","article-title":"Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro: implications for mechanism of action of and resistance to the drug","volume":"40","author":"Geary","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.arabjc.2021.103385_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101873","article-title":"Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation","volume":"37","author":"Gendrot","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"15","key":"10.1016\/j.arabjc.2021.103385_b0230","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arabjc.2021.103385_b0235","doi-asserted-by":"crossref","unstructured":"Gregoire, M., et al., Lopinavir pharmacokinetics in COVID-19 patients. J. Antimicrob. Chemotherapy, 2020. 75: p. 2702\u20132704.","DOI":"10.1093\/jac\/dkaa195"},{"issue":"24","key":"10.1016\/j.arabjc.2021.103385_b0240","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.arabjc.2021.103385_b0245","first-page":"776","article-title":"Anti-malarial and cytokine-modulating effects of andrographolide in a murine model of malarial infection","volume":"36","author":"Hassan","year":"2019","journal-title":"Trop. Biomed."},{"issue":"2","key":"10.1016\/j.arabjc.2021.103385_b0250","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.arabjc.2021.103385_b0255","doi-asserted-by":"crossref","unstructured":"Hodge, C., et al., Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J. Antimicrob. Chemother., 2020. 75, 12, p. 3417-3424.","DOI":"10.1093\/jac\/dkaa340"},{"issue":"10259","key":"10.1016\/j.arabjc.2021.103385_b0260","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.arabjc.2021.103385_b0265","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1177\/0961203318787040","article-title":"Hydroxychloroquine: an update","volume":"27","author":"Hughes","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.arabjc.2021.103385_b0270","first-page":"1","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor","author":"Humeniuk","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.arabjc.2021.103385_b0275","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of Favipiravir in critically ill patients with COVID-19","volume":"13","author":"Irie","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.arabjc.2021.103385_b0280","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.14335","article-title":"COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?","volume":"86","author":"Javelot","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.arabjc.2021.103385_b0285","first-page":"174","article-title":"Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty","volume":"144","author":"Johnson","year":"1979","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"9","key":"10.1016\/j.arabjc.2021.103385_b0290","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jiph.2020.07.013","article-title":"Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review","volume":"13","author":"Jomah","year":"2020","journal-title":"J. Infect. Publ. Health"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0295","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy: J. Hum. Pharmacol. Drug Therapy"},{"key":"10.1016\/j.arabjc.2021.103385_b0300","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"17","key":"10.1016\/j.arabjc.2021.103385_b0305","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.arabjc.2021.103385_b0310","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S287934","article-title":"Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database","volume":"13","author":"Kaur","year":"2020","journal-title":"Infect. Drug Resistance"},{"key":"10.1016\/j.arabjc.2021.103385_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110110","article-title":"Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19","volume":"143","author":"Kavanagh","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.arabjc.2021.103385_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109783","article-title":"Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection","volume":"142","author":"Klimke","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.arabjc.2021.103385_b0330","article-title":"Cardiac arrhythmias in COVID-19 infection","volume":"13","author":"Kochav","year":"2020","journal-title":"Circulation: Arrhythmia Electrophysiol."},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.arabjc.2021.103385_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111642","article-title":"Disease-drug and drug-drug interaction in COVID-19: risk and assessment","author":"Kumar","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.arabjc.2021.103385_b0345","doi-asserted-by":"crossref","unstructured":"Lai, C.-C., et al., Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J. Antimicrob. Chemother., 2021. 76, 8, p. 1962\u20131968.","DOI":"10.1093\/jac\/dkab093"},{"key":"10.1016\/j.arabjc.2021.103385_b0350","doi-asserted-by":"crossref","unstructured":"Lemaitre, F., et al., Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam. Clin. Pharmacol., 2020. 34, 5, p. 530-547.","DOI":"10.1111\/fcp.12586"},{"key":"10.1016\/j.arabjc.2021.103385_b0355","article-title":"Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.arabjc.2021.103385_b0360","article-title":"The Influence of Virus Infection on the Extracellular pH of the Host Cell Detected on Cell Membrane","volume":"7","author":"Liu","year":"2016","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.arabjc.2021.103385_b0365","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0370","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06164-x","article-title":"Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis","volume":"21","author":"Manabe","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.arabjc.2021.103385_b0375","doi-asserted-by":"crossref","unstructured":"Marra, F., et al., Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment. Drugs in R&D, 2020: p. 1\u201319.","DOI":"10.1007\/s40268-020-00333-0"},{"key":"10.1016\/j.arabjc.2021.103385_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.arabjc.2021.103385_b0385","unstructured":"Mohammad reza, M., Morteza, A.-Z., 2020. Safety and effectiveness of favipiravir for novel coronavirus (COVID-19): a rapid review of available evidence. Health Technol. Assess. Action, 4, 1."},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0390","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450\u2013mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0395","first-page":"737","article-title":"Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature","volume":"21","author":"Musa","year":"2020","journal-title":"West J. Emerg. Med."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0400","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.14730","article-title":"Pathophysiological mechanisms of liver injury in COVID-19","volume":"41","author":"Nardo","year":"2021","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.arabjc.2021.103385_b0405","first-page":"481","article-title":"Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences","volume":"29","author":"Nasir","year":"2020","journal-title":"Mymensingh Med. J."},{"issue":"2","key":"10.1016\/j.arabjc.2021.103385_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.arabjc.2021.103385_b0415","doi-asserted-by":"crossref","unstructured":"Ofotokun, I., et al., 2011. Immune activation mediated change in alpha\u20101\u2010acid glycoprotein: impact on total and free lopinavir plasma exposure. J. Clin. Pharmacol., 51, 11, p. 1539\u20131548.","DOI":"10.1177\/0091270010385118"},{"issue":"9","key":"10.1016\/j.arabjc.2021.103385_b0420","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s00134-020-06142-y","article-title":"Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study","volume":"46","author":"Painvin","year":"2020","journal-title":"Intensive Care Med."},{"issue":"6","key":"10.1016\/j.arabjc.2021.103385_b0425","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0430","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: from Ebola to COVID-19","volume":"9","author":"Pardo","year":"2020","journal-title":"Drugs Context"},{"issue":"12","key":"10.1016\/j.arabjc.2021.103385_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243705","article-title":"Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis","volume":"15","author":"Piscoya","year":"2020","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.arabjc.2021.103385_b0440","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41379-020-0603-3","article-title":"A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression","volume":"33","author":"Polak","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.arabjc.2021.103385_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100776","article-title":"Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review","volume":"38","author":"Prodromos","year":"2020","journal-title":"New Microbes New Infect."},{"issue":"3","key":"10.1016\/j.arabjc.2021.103385_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell reports"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0455","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/v13071369","article-title":"Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19","volume":"13","author":"Rasmussen","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.arabjc.2021.103385_b0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amsu.2020.12.051","article-title":"Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Reddy Vegivinti","year":"2021","journal-title":"Ann. Med. Surg. (Lond.)"},{"key":"10.1016\/j.arabjc.2021.103385_b0465","unstructured":"UPTODATE. Remdesivir: Drug information. 2021 25 April 2021]; Available from: https:\/\/0o112ngb4-y-https-www-uptodate-com.kau.proxy.deepknowledge.io\/contents\/remdesivir-drug-information."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0470","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.705","article-title":"Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview","volume":"9","author":"Rezaee","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.arabjc.2021.103385_b0475","unstructured":"Roser, M., et al. Coronavirus pandemic (COVID-19). Our world in data 2021 [cited 2021 29 June]; Available from: https:\/\/ourworldindata.org\/coronavirus."},{"issue":"9","key":"10.1016\/j.arabjc.2021.103385_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100146","article-title":"Hydroxychloroquine Inhibits the trained innate immune response to interferons","volume":"1","author":"Rother","year":"2020","journal-title":"Cell Reports Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0485","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/TCRM.S301817","article-title":"Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19: A fiction, hope or hype? An updated review","volume":"17","author":"Saghir","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.arabjc.2021.103385_b0490","article-title":"In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters","volume":"3","author":"Sahakijpijarn","year":"2021","journal-title":"Int. J. Pharmaceut.: X"},{"key":"10.1016\/j.arabjc.2021.103385_b0495","doi-asserted-by":"crossref","unstructured":"Sahraei, Z., et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int. J. Antimicrob. Agents, 2020. 105945.","DOI":"10.1016\/j.ijantimicag.2020.105945"},{"issue":"18","key":"10.1016\/j.arabjc.2021.103385_b0500","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0505","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/jmv.25898","article-title":"Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis","volume":"92","author":"Sarma","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.arabjc.2021.103385_b0510","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acsinfecdis.0c00343","article-title":"Old drugs for a new virus: repurposed approaches for combating COVID-19","volume":"6","author":"Saul","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"11","key":"10.1016\/j.arabjc.2021.103385_b0515","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.arabjc.2021.103385_b0520","first-page":"1","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.arabjc.2021.103385_b0525","first-page":"192","article-title":"Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials","volume":"28","author":"Shittu","year":"2020","journal-title":"Infez Med"},{"key":"10.1016\/j.arabjc.2021.103385_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118663","article-title":"Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis","volume":"264","author":"Shrestha","year":"2021","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.arabjc.2021.103385_b0535","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","article-title":"Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metabolic Syndrome"},{"issue":"8","key":"10.1016\/j.arabjc.2021.103385_b0540","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s42399-020-00399-6","article-title":"Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials","volume":"2","author":"Siordia","year":"2020","journal-title":"SN Comprehensive Clin. Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0545","first-page":"1","article-title":"Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer aditional benefit","volume":"22","author":"Sun","year":"2020","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0550","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/cts.12923","article-title":"A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study","volume":"14","author":"Tai","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0555","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-020-00143-y","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"npj Genomic Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0565","doi-asserted-by":"crossref","unstructured":"Tobaiqy, M., Alhumaid, S., Mutair, A.A., 2020. Efficacy and Safety of Lopinavir\/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. medRxiv, p. 2020.06.16.20133298.","DOI":"10.1101\/2020.06.16.20133298"},{"key":"10.1016\/j.arabjc.2021.103385_b0570","doi-asserted-by":"crossref","unstructured":"Touafchia, A., et al., 2021. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clinical Microbiology and Infection, 27, 5, p. 791. e5-791. e8.","DOI":"10.1016\/j.cmi.2021.02.013"},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0575","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70143-6","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret","year":"2020","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.arabjc.2021.103385_b0580","first-page":"8592","article-title":"Lopinavir\/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review","volume":"24","author":"Vargas","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.arabjc.2021.103385_b0585","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"21","key":"10.1016\/j.arabjc.2021.103385_b0590","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1111\/bph.15102","article-title":"Lung tissue distribution of drugs as a key factor for COVID-19 treatment","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arabjc.2021.103385_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173634","article-title":"Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment","volume":"889","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.arabjc.2021.103385_b0600","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.arabjc.2021.103385_b0605","doi-asserted-by":"crossref","unstructured":"Yan, V.C., et al., Pharmacokinetics of Orally Administered GS-441524 in Dogs. bioRxiv, 2021: p. 2021.02.04.429674.","DOI":"10.1101\/2021.02.04.429674"},{"issue":"10","key":"10.1016\/j.arabjc.2021.103385_b0610","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.7150\/ijbs.45538","article-title":"Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.arabjc.2021.103385_b0615","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respirat. Med."},{"key":"10.1016\/j.arabjc.2021.103385_b0620","doi-asserted-by":"crossref","unstructured":"Yao, X., et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical infectious diseases, 2020. 71(15): p. 732-739.","DOI":"10.1093\/cid\/ciaa237"},{"key":"10.1016\/j.arabjc.2021.103385_b0625","first-page":"1","author":"Zeitlinger","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.arabjc.2021.103385_b0630","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerging Microbes Infect."},{"issue":"10","key":"10.1016\/j.arabjc.2021.103385_b0635","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200674","article-title":"Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies","volume":"217","author":"Zhou","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.arabjc.2021.103385_b0640","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cts.12866","article-title":"Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)","volume":"13","author":"Zubiaur","year":"2020","journal-title":"Clin. Transl. Sci."}],"container-title":["Arabian Journal of Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878535221004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878535221004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T21:07:28Z","timestamp":1751058448000},"score":1,"resource":{"primary":{"URL":"https:\/\/arabjchem.org\/scoping-insight-on-antiviral-drugs-against-covid-19\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":126,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1878535221004007"],"URL":"https:\/\/doi.org\/10.1016\/j.arabjc.2021.103385","relation":{},"ISSN":["1878-5352"],"issn-type":[{"type":"print","value":"1878-5352"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scoping insight on antiviral drugs against COVID-19","name":"articletitle","label":"Article Title"},{"value":"Arabian Journal of Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arabjc.2021.103385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"103385"}}